You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, May 2018
|
| DOI | 10.1186/s40425-018-0342-x |
| Pubmed ID | |
| Authors |
Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley |
| Abstract |
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval. |
X Demographics
The data shown below were collected from the profiles of 27 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 26% |
| Croatia | 1 | 4% |
| Spain | 1 | 4% |
| Poland | 1 | 4% |
| Brazil | 1 | 4% |
| France | 1 | 4% |
| India | 1 | 4% |
| Singapore | 1 | 4% |
| Unknown | 13 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 67% |
| Practitioners (doctors, other healthcare professionals) | 5 | 19% |
| Scientists | 3 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 182 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 182 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 28 | 15% |
| Student > Bachelor | 26 | 14% |
| Researcher | 21 | 12% |
| Student > Ph. D. Student | 20 | 11% |
| Student > Doctoral Student | 12 | 7% |
| Other | 22 | 12% |
| Unknown | 53 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 26% |
| Biochemistry, Genetics and Molecular Biology | 32 | 18% |
| Agricultural and Biological Sciences | 14 | 8% |
| Immunology and Microbiology | 8 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
| Other | 13 | 7% |
| Unknown | 64 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2023.
All research outputs
#1,488,987
of 25,382,440 outputs
Outputs from Journal for Immunotherapy of Cancer
#379
of 3,422 outputs
Outputs of similar age
#31,636
of 340,921 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#13
of 40 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,921 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.